Koa Wealth Management LLC Grows Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Koa Wealth Management LLC lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 7.7% during the third quarter, Holdings Channel reports. The institutional investor owned 3,770 shares of the medical device company’s stock after buying an additional 270 shares during the quarter. Koa Wealth Management LLC’s holdings in DexCom were worth $253,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Taylor Frigon Capital Management LLC increased its holdings in DexCom by 51.6% in the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock valued at $2,182,000 after buying an additional 11,075 shares in the last quarter. Brooktree Capital Management purchased a new stake in shares of DexCom during the third quarter worth about $683,000. National Pension Service lifted its stake in DexCom by 4.1% in the 3rd quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after buying an additional 37,363 shares in the last quarter. Intact Investment Management Inc. purchased a new position in DexCom in the 3rd quarter valued at about $650,000. Finally, Waters Parkerson & CO. LLC boosted its holdings in DexCom by 4.2% in the 2nd quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock worth $30,912,000 after buying an additional 10,892 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Activity

In other DexCom news, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This trade represents a 0.56 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the topic of several research reports. Leerink Partners decreased their target price on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Royal Bank of Canada lowered their price target on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Stifel Nicolaus boosted their target price on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. Finally, JPMorgan Chase & Co. increased their price target on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $104.59.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $75.88 on Friday. The stock has a market cap of $29.64 billion, a P/E ratio of 45.44, a P/E/G ratio of 2.22 and a beta of 1.17. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The stock has a 50 day moving average of $70.03 and a two-hundred day moving average of $91.67. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.